This report was first published by Endpoints News. To see the original version, click here
The government on Tuesday announced final prices for the second round of drugs negotiated by Medicare under the Inflation Reduction Act, including for Novo Nordisk’s blockbuster semaglutide products Ozempic and Wegovy.
The negotiated prices are up to 85% lower than the list prices for the drugs.
您已閱讀8%（385字），剩余92%（4707字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。